2025 European Society for Medical Oncology (ESMO) Annual Congress
ESMO 2025 Prostate Cancer
- ESMO 2025: Discussant – PR.21 and LUNAR Trials
- ESMO 2025: Optimized Use of Endocrine Therapies and Chemotherapies in mCRPC
- ESMO 2025: Optimized Use of Radioligand Therapy in mCRPC
- ESMO 2025: Optimized Use of Immunotherapy and Targeted Therapies in mCRPC
- ESMO 2025: A Randomized Phase II study of 177Lu-PSMA-617 versus Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and PSMA-positive Disease: Canadian Cancer Trials Group (CCTG) Study PR.21
ESMO 2025 Bladder Cancer
- ESMO 2025: TiP: INTerpath-011: A Phase 2 Study of Intismeran Autogene (V940/mRNA-4157) + BCG Versus BCG Alone for High-Risk NMIBC
- ESMO 2025: EORTC GUCG 2418 STARBUST: Strategies for Treatment Adaptation Following Re-Evaluation of the Bladder After Using pRimary Neoadjuvant Systemic Therapies: An EORTC Platform Trial
- ESMO 2025: Enfortumab Vedotin with Pembrolizumab Treatment Outcomes in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study
- ESMO 2025: Discussant: Precision in the Adjuvant Gap – IMvigor011 and ctDNA+ MIBC
- ESMO 2025: Cost-Effectiveness Analysis of Perioperative Durvalumab plus Platin-Based Chemotherapy in Muscle Invasive Bladder Cancer
ESMO 2025 Kidney Cancer
- ESMO 2025: Invited Discussant: KEYMAKER-UO3 Substudy 03A, LenCabo, & OPTIC RCC
- ESMO 2025: Final Analysis of Lenvatinib + Pembrolizumab versus Sunitinib in Patients with Advanced RCC with or Without Bone Metastases in CLEAR
- ESMO 2025: Durability of Complete Response to First Line in Metastatic Renal Cell Carcinoma in the Real World
- ESMO 2025: Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear Cell Renal Cell Carcinoma: a Multicentre Single-Arm Phase II Trial (RENALUT)
- ESMO 2025: EXPLORE-RCC: A Phase II Study of Neoadjuvant Zanzalintinib plus Nivolumab in Patients with Locally Advanced And/or Inoperable Clear Cell Renal Cell Carcinoma (ccRCC)
ESMO 2025 Upper Tract Urothelial Carcinoma
ESMO 2025 Testicular and Penile Cancer
- ESMO 2025: Final Results of the COTRIMS (COlogne Trial of Retroperitoneal Lymphadectomy in Metastastic Seminoma) Trial
- ESMO 2025: Post-Diagnosis Paternity in Testicular Cancer Survivors: A Controlled Cohort Study
- ESMO 2025: Discussion: Long-Term SAKK 01/10 Seminoma Outcomes and the ALPACA Avelumab Study
- ESMO 2025: A Phase 2 Study of Avelumab in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-Based Chemotherapy or Progressed on or after Platinum-Based Chemotherapy (ALPACA)
- ESMO 2025: Single-Dose Carboplatin and Involved-Node Radiotherapy for Seminoma Stage IIA/B: Long-Term Follow-up from the International Multicenter Phase II Trial SAKK 01/10